Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome

Franco, Juan Víctor Ariel; Turk, Tarek; Jung, Jae Hung; Yu, Xiaobing; Iakhno, Stanislav; Garrote, Virginia; Vietto, Valeria

doi:10.1002/14651858.cd012551.pub3

Cited by 75 publications

(49 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This systematic review and meta‐analysis was based on published protocol . We performed a comprehensive search using multiple databases of the Cochrane Central Register of Controlled Trials (1987–2017, issue 7) in the Cochrane Library: MEDLINE Ovid (1946 to 11 August 2017); EMBASE Elsevier (1974 to 11 August 2017); PsycINFO Ovid (1887 to 11 August 2017); CINAHL EBSCO (1937 to 11 August 2017); ClinicalTrials.gov (http://www.clinicaltrials.gov, 14 August 2017); ISRCTN Registry (BioMed Central; http://www.isrctn.com/, 14 August 2017); and the World Health Organization International Clinical Trials Registry Platform (http://www.who.int/trialsearch, 14 August 2017).…”

Section: Methodsmentioning

confidence: 99%

Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review

et al. 2019

Self Cite

View full text Add to dashboard Cite

Based on the findings of moderate to high-quality evidence, this review found that some non-pharmacological interventions such as acupuncture and extracorporeal shockwave therapy are likely to result in a decrease in prostatitis symptoms and may not be associated with a greater incidence of adverse event. The QoE for most other comparisons was predominantly low. Future clinical trials should include a full report of their methods including adequate masking, consistent assessment of all patient-important outcomes including potential treatment-related adverse events and appropriate sample sizes. This article is protected by copyright. All rights reserved.

show abstract

Section: Methodsmentioning

confidence: 99%

Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Regarding to the hyperthermia therapy, our finding is similar to the results from one Cochrane review. [33] In our review, hyperthermia therapy was superior to Prostant in improving the symptoms of CP. In the precious Cochrane review [33] assessing the effect and safety of all kinds of nonpharmaceutical treatment for CP included 2 trials with transrectal thermotherapy (237 participants).…”

Section: Discussionmentioning

confidence: 97%

“…[33] In our review, hyperthermia therapy was superior to Prostant in improving the symptoms of CP. In the precious Cochrane review [33] assessing the effect and safety of all kinds of nonpharmaceutical treatment for CP included 2 trials with transrectal thermotherapy (237 participants). Based on short-term follow-up, low-quality evidence showed transrectal thermotherapy alone or in combination with medical therapy may decrease prostatitis symptoms slightly when compared with medical therapy alone (NIH-CPSI score MD −2.50, 95% CI −3.82 to −1.18).…”

Section: Discussionmentioning

confidence: 99%

Qian lie an suppository (prostant) for chronic prostatitis

et al. 2019

View full text Add to dashboard Cite

Background: Chronic prostatitis (CP) is an inflammation of the prostate gland that seriously affects the quality of life of patients. The existing evidence of antibiotics and α-blockers for the treatment of CP is limited. Objectives: This review evaluated the effectiveness and safety of Qian Lie An Suppository (Prostant) in treating CP. Methods: Randomized controlled trials comparing Prostant (alone or plus the control) with placebo, conventional drugs, or nonpharmaceutical therapies for CP were included in this article through searching from 6 databases. Data were analyzed using RevMan 5.3 software. Meta-analysis was performed when the clinical or statistical heterogeneity was found acceptable among trials. Estimate effects were present with risk ratio (RR) or mean difference and their 95% confidence interval (CI) for dichotomies or continuous variables. Quality of the evidence for each primary outcome was assessed using GRADE criteria. Results: Totally 21 trials involving 3359 participants were included. There were 2 included trials had unclear risk of bias, and the remaining trials had high risk of bias. Meta-analyses showed the number of cured patients in the Prostant group was 2 times more than that of the placebo (RR 2.05, 95%CI 1.10 to 3.81) or antibiotics (RR 1.95, 95%CI 1.18 to 3.23) groups. Similar results were found when Prostant in combination with antibiotics or hyperthermia compared with the antibiotics (RR 1.78, 95% CI 1.10–2.89) or hyperthermia (RR 1.72, 95% CI 1.23–2.40) alone. However, there was no difference in the number of cured patients between Prostant and α-blockers or hyperthermia therapy. No severe adverse event was reported in all included trials. The main adverse events in Prostant group were reported (in 8 included trials) as diarrhea and anal discomfort. Conclusions: Low-quality evidence showed that the Prostant may have add-on effect for patients with CP on increasing the number of cured patients, relieving pain, and improving the quality of life. There is not sufficient evidence to determine the effectiveness and safety of Prostant for the treatment of CP compared with placebo, antibiotics, α-blockers or the hyperthermia therapy.

show abstract

“…Prostatitis is a common disease in adult men, with an incidence rate of approximately 10%–14% (Franco et al, ). Prostatitis patients account for 25% of the total number of outpatients in the department of urology, and the recurrence rate of prostatitis is 20%–50% (Krieger & Riley, ).…”

Section: Introductionmentioning

confidence: 99%

Upregulation of TRPV1 in spinal dorsal root ganglion by activating NGF‐TrkA pathway contributes to pelvic organ cross‐sensitisation in rats with experimental autoimmune prostatitis

Zhang

Gong

et al. 2019

Andrologia

View full text Add to dashboard Cite

Chronic prostatitis/chronic pelvic pain syndrome (CP⁄CPPS) is the prostate gland inflammation characterised as genitourinary pain in the pelvic region. The rat experimental autoimmune prostatitis (EAP) was achieved to mimic CP⁄CPPS. The expressions of transient receptor potential vanilloid 1 (TRPV1) in the prostate, bladder and spinal dorsal root ganglion (DRG) were analysed by Western blotting. Tropomyosin receptor kinase A (TrkA) and nerve growth factor (NGF) in the DRG were also analysed by Western blotting. Measurements of inflammatory cytokines were carried out according to the instructions of the corresponding kits. The expressions of TRPV1 in the prostate, bladder and DRG in the EAP group were significantly higher than those in the control group. The expressions of NGF and TrkA in the DRG in the EAP group were significantly higher than those in the control group. The levels of serum TNF-α and IL-1β in the EAP group were significantly higher than those in the control group. We conclude that CP⁄CPPS may participate in the pathological activation of neurons in the L5-S1 segment of DRG by activating NGF-TrkA pathway and cause pelvic organ cross-sensitisation by upregulating the expression of TRPV1 in the prostate, bladder and DRG. K E Y W O R D Schronic prostatitis/chronic pelvic pain syndrome, cross-sensitisation, NGF-TrkA pathway, transient receptor potential vanilloid 1

show abstract

Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome

Cited by 75 publications

References 144 publications

Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review

Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review

Qian lie an suppository (prostant) for chronic prostatitis

Upregulation of TRPV1 in spinal dorsal root ganglion by activating NGF‐TrkA pathway contributes to pelvic organ cross‐sensitisation in rats with experimental autoimmune prostatitis

Contact Info

Product

Resources

About